Hledat klinickou studii
38 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
SPOJENÉ KRÁLOVSTVÍ
Tyne & Wear
NEWCASTLE-UPON-TYNE
EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide
Newcastle University
Newcastle Clinical Trials Unit
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - AT
Institution: Information not provided - AT
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STATIN: Étude contrôlée et randomisée visant à évaluer la pravastatine versus placebo pour la prévention de la prééclampsie - BE
CHU Brugmann
Service de médecine foetale / Fetal medicine department
BELGIE
VLAAMS BRABANT
LEUVEN
ASPRE-T: Aspirine versus placebo bij tweelingzwangerschappen voor pre-eclampsiepreventie: een multicenter, gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie - BE
UZ Leuven - Campus Gasthuisberg
Dienst Gynaecologie en Verloskunde / Clinical Department of Obstetrics and Gynaecology
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
ASPRE-T: Aspirin versus Placebo bei Zwillingsschwangerschaften zur Prävention der Präeklampsie: eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie
Institution: Information not provided - DE
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ASPRE-T: Aspirina versus placebo nelle gravidanze gemellari per la prevenzione della preeclampsia: uno studio multicentrico, randomizzato, in doppio cieco, controllato con placebo
Institution: Information not provided - IT
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ASPRE-T: Aspirina versus placebo en embarazos gemelares para la prevención de la preeclampsia: un ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo -ES
Institution: Information not provided - ES
ŠVÉDSKO
Region Stockholm
SOLNA
Effekter av Nitrat-rik rödbetsjuice hos gravida kvinnor med högt blodtryck - SE
Karolinska Institutet
Department of Physiology and Pharmacology (FYFA)
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II)
University College London Hospitals, NHS Foundation Trust
Endocrinology Department
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Phase II Study of Nicotinamide in Early Onset Preeclampsia
Institution: Information not provided - US
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
REAL 8: A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature - AT
Institution: Information not provided - AT
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
hSCU-PRP: Plasma rico en plaquetas procedente de cordón umbilical para el tratamiento de patologías endometriales (endometrio fino/ Síndrome de Asherman/ Atrofia endometrial): un estudio piloto
Hospital Universitario y Politécnico La Fe
Servicio de Obstetricia y Ginecología
BELGIE
OOST-VLAANDEREN
GENT
Essai d'extension à long terme portant sur la setmélanotide (RM-493) chez des patients ayant terminé un essai utilisant la setmélanotide dans le traitement de l'obésité liée à des défauts génétiques en amont du récepteur aux mélanocortines de type 4 (MC4R) dans la voie leptine-mélanocortine - BE
Ghent University Hospital - UZ Gent
Ghent University Hospital
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - CA
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Essai de phase 3, randomisé, en double aveugle, évaluant deux formulations de setmelanotide (quotidienne et hebdomadaire) suivi du setmelanotide hebdomadaire en ouvert chez les patients présentant des anomalies génétiques spécifiques de la voie du récepteur de la mélanocortine-4 et traités actuellement avec une dose stable de la formulation quotidienne -FR
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Étude de phase 2 randomisée, en double aveugle, contrôlée par placebo, multicentrique, en deux parties, évaluant l'efficacité, l'innocuité et la tolérance du RGH-706 chez les patients atteints du syndrome de Prader-Willi -FR
Institution: Information not provided - FR
FRANCIE
OCCITANIE
TOULOUSE
OXYJEUNE : Effets d'administrations intranasales d'ocytocine sur l'anxiété, les troubles du comportement et l'hyperphagie chez des enfants âgés de 3 à 12 ans présentant un syndrome de Prader-Willi (Phase III)
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
FRANCIE
OCCITANIE
TOULOUSE
Étude interventionnelle de suivi à long terme jusqu'à l'âge de 4 ans des enfants atteints du syndrome de Prader-Willi inclus dans l'essai clinique OTBB3 et comparaison avec une cohorte non traitée d'enfants atteints du syndrome de Prader-Willi. -FR
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
NĚMECKO
Baden-Württemberg
ULM
Eine offene, einjährige Studie mit einer doppelblinden, Placebo-kontrollierten Entzugsperiode von Setmelanotide (RM-493), einem Melanocortin-4-Rezeptor (MC4R)-Agonisten, bei früh einsetzender Leptin-Rezeptor (LEPR)-Mangel-Adipositas durch LEPR-Genmutation mit bi-allelischen Funktionsverlust
Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
Zentrum für Seltene Erkrankungen (ZSE) ULM
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte Phase-3-Doppelblindstudie mit zwei Setmelanotid-Formulierungen (täglich und wöchentlich) mit einem Crossover zu einmal wöchentlichem Setmelanotid mit offener Zulassung bei Patienten mit spezifischen Gendefekten im Melanocortin-4-Rezeptor-Signalweg, die derzeit eine stabile Dosis der einmal täglichen Formulierung erhalten
Institution: Information not provided - DE
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio randomizzato, in doppio cieco, controllato con placebo, multicentrico, in 2 parti, di fase 2, per valutare l'efficacia, la sicurezza e la tollerabilità di RGH-706 nella sindrome di Prader-Willi
Institution: Information not provided - IT
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
Dutch Growth Hormone Cohort study in children with Prader-Willi syndrome: Long-term effects on growth, body composition, activity level and psychosocial development
Stichting Kind en Groei
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
Behandeling met N-acetylcysteïne voor skin picking gedrag in kinderen en jongvolwassenen met PWS: een gerandomiseerde, gecontroleerde, cross-over studie
Stichting Kind en Groei
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
MADRID
Estudio abierto de fase III, multicéntrico y de un año de setmelanotida en pacientes pediátricos de 2 a <6 años de edad con causas genéticas raras de obesidad -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -GB
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Merseyside
LIVERPOOL
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
Fazakerley Hospital
University Hospital Aintree - Diabetes and Endocrinology
SPOJENÉ KRÁLOVSTVÍ
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Institution: Information not provided - US
Nadnárodní klinické studie
AUSTRÁLIE
Victoria
ADDRESS: NOT PROVIDED - AU
A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruritus. - TURRIFIC Protocol Version 8
Institution: Information not provided - AU
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT)A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4.0 mg of Folic Acid supplementation in pregnancy for the prevention of preeclampsia - Folic Acid Clinical Trial (FACT)
Institution: Information not provided - CA
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial.
King's College Hospital
Harris Birthright Research Centre for Fetal Medicine
MAĎARSKO
Dél-Dunántúl
ADDRESS: NOT PROVIDED - HU
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome.
Institution: Information not provided - HU
NIZOZEMSKO
Utrecht
ADDRESS: NOT PROVIDED - NL
Global Growth Hormone Study in Adults With Prader-Willi Syndroom
Institution: Information not provided - NL
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
ZEPHYR: A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analog, on Food-related Behaviors in Patients With Prader-Willi Syndrome
Millendo Therapeutics Ltd
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US